Abstract:Toremifene has also been studied as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. In that setting, three large randomized trials comprising 3747 postmenopausal women demonstrated that toremifene and tamoxifen are equivalent in efficacy and safety [4][5][6] . However, despite those three trials, toremifene is not approved for that indication in any jurisdiction. Given the extensive clinical data supporting the use of ais as adjuvant treatment in endocrine-responsive breas… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.